Across TCGA pan-cancer cohorts, SESTD1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SESTD1 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SESTD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SESTD1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, UCEC, and SCLC are the cancer types where SESTD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.352	0.692	.013	36	view →
UCEC	DFS	Median	II,III,IV	0.937	0.426	.006	26	view →
SCLC	OS	Median	All	0.301	0.716	.003	12	view →
LUAD	OS	Median	II,III,IV	0.364	0.752	.012	9	view →
LUSC	OS	Median	II,III,IV	0.043	0.781	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SESTD1 tumor-vs-normal RNA expression · all SESTD1 data types